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Central tolerance can be mediated by peripheral
dendritic cells (DCs) that transport innocuous
antigens (Ags) to the thymus for presentation to
developing T cells, but the responsible DC subsets
remained poorly defined. Immature plasmacytoid
DCs (pDCs) express CCR9, a chemokine receptor
involved in migration of T cell precursors to the
thymus. We show here that CCR9 mediated efficient
thymic entry of endogenous or i.v. transfused pDCs.
pDCs activated by Toll-like receptor (TLR) ligands
downregulated CCR9 and lost their ability to home
to the thymus. Moreover, endogenous pDCs took
up subcutaneously injected fluorescent Ag and, in
the absence of TLR signals, transported Ag to the
thymus in a CCR9-dependent fashion. Injected, Ag-
loaded pDCs effectively deleted Ag-specific thymo-
cytes, and this thymic clonal deletion required
CCR9-mediated homing andwas prevented by infec-
tious signals. Thus, peripheral pDCs can contribute
to immune tolerance through CCR9-dependent
transport of peripheral Ags and subsequent deletion
of Ag-reactive thymocytes.
INTRODUCTION
Central (thymic) tolerance requires that self-antigens, including
tissue-specific antigens (TSAs), be available in the thymus to
be processed and presented on MHC molecules to developing
thymocytes. Some soluble antigens (Ags) can access the
thymus from the blood and be presented to thymocytes by
thymic dendritic cell (DC) populations (Wu and Shortman,
2005). Other peripheral TSAs can be expressed by medullary
thymic epithelial cells (mTECs) under the control of the transcrip-
tion factor AIRE and deficiencies in this gene have been shown to
lead to organ-specific autoimmunity (Anderson et al., 2002).
AIRE-independent mechanisms for thymic epithelial expression
of peripheral Agsmay also exist (Derbinski et al., 2005), but these438 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.transcriptional mechanisms are not likely to allow expression of
all self-Ags present within the body at sufficient levels for presen-
tation to developing T cells. Moreover, they cannot present
innocuous non-self Ags, such as food Ags or ubiquitous prod-
ucts of commensal flora that may enter the body. Therefore,
alternative mechanisms must exist to broaden the spectrum of
self-Ags presented to developing T cells.
Recent studies suggest that migratory DC populations can
transport peripheral Ags to the thymus for central tolerance.
Bulk splenic DCs, loaded with peptide Ag and injected intrave-
nously (i.v.), can access the thymus and induce deletion of
developing Ag-specific T cells expressing a transgenic T cell
receptor (TCR) (Bonasio et al., 2006). Importantly, up to 50% of
thymic DCs arrive from the peripheral circulation (Donskoy and
Goldschneider, 2003). Three subtypes of thymic DCs have
been characterized: plasmacytoid DCs (pDCs) and two pheno-
typically and functionally distinct subsets of conventional DCs
(cDCs) (Li et al., 2009). The thymic cDCpopulations aredescribed
as CD8aloCD11b+ signal-regulatory protein alpha+ (SIRPa+)
cDCs and CD8ahiCD11bSIRPa cDCs (Li et al., 2009). The
SIRPa thymic cDC population arises from intrathymic precur-
sors and does not exchange with the circulating peripheral DC
pool (Li et al., 2009). The SIRPa+ cDC population, on the other
hand, migrates into the thymus from the blood (Li et al., 2009)
and in vitro coculture assays have shown that this DC population
mediates clonal deletion of as well as regulatory T (Treg) cell
induction from developing thymocytes (Proietto et al., 2008).
Less is known about the migration and intrathymic function of
pDCs. Immature pDCs induce immune tolerance in the periphery
through the induction of Treg cells (Morelli and Thomson, 2007),
but they are also important innate immunecells that produce type
I interferons in response to viral infections (Colonna et al., 2004).
Thymic pDCs are derived from the blood circulation, as opposed
to originating from intrathymic precursors (Li et al., 2009), but
unlike migratory cDCs, thymic pDCs do not efficiently induce
Treg cells from thymocytes in vitro (Proietto et al., 2008). More-
over, they are poor presenters of Ags in the absence of microbial
stimulation (Colonna et al., 2004). Plasmacytoid DC-derived type
I interferons influence themigration and function of cDCs, but this
also requires microbial stimulation (Colonna et al., 2004), which
makes their role unclear in the steady-state thymus. It has been
suggested that the function of pDCs within the thymus, as in
Figure 1. CCR9 Controls pDC Representation in the Thymus under Competitive and Noncompetitive Conditions
(A) Blood leukocytes and cell suspensions from thymi, spleen, peripheral lymph nodes (PLN), and mesenteric lymph nodes (MLN) from untreated C57BL/6 (WT)
and Ccr9/ mice were analyzed by flow cytometry for the number of lineage (lin) (CD3, CD19, NK1.1) pDCs (CD11cintB220+PDCA-1+) and cDCs
(CD11chiB220PDCA-1) as well as thymic SIRPa+ (CD11b+) and SIRPa (CD11b) cDCs. Bar graphs present the mean number of DCs per million live cells with
error bars showing the standard error of the mean (SEM) (five mice per group) from one of two experiments.
(B and C) Bone marrow chimeras (BMC) were generated by reconstituting lethally irradiated WT F1 (CD45.1 3 CD45.2) mice with equal numbers of ‘‘experi-
mental’’Ccr9/ (CD45.2) bonemarrow (BM) cellsmixedwith congenicWT (CD45.1) BMcells (white bars) or ‘‘control’’WT (CD45.2) BMcellsmixedwith congenic
WT (CD45.1) BM cells (black bars). Tissues were harvested 8–12 weeks later and cell suspensions analyzed by flow cytometry. To assess BM engraftment
efficiency of each donor type, the CD45.1/CD45.2 ratio for BM-derived splenic CD19+ B cells was determined. For each mouse, the CD45.1/CD45.2 ratio
among gated (LinCD11cintB220+) pDCs in each tissue was normalized for the engraftment efficiency to yield normalized localization ratios (R): R = (CD45.1/
CD45.2)Tissue pDCs/(CD45.1/CD45.2)Splenic B cells. Reconstituted chimeric mice in (B) were evaluated without further treatment, whereas the pDCs in BMCs in (C)
were expanded by inoculation of mice with Flt3L-secreting B16 tumors. Error bars represent the SEM.
Overall, results are representative of three experiments with four to five BMC pairs analyzed. See also Figure S1.
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infections (Wu and Shortman, 2005).
We have recently shown that tolerogenic pDCs in lymphoid
tissues express the chemokine receptor CCR9 (Hadeiba et al.,
2008), a chemoattractant receptor involved in homing ofmemory
and effector lymphocyte populations to the small intestines
(Kunkel et al., 2000; Pabst et al., 2004) and also in progenitor
T cell homing to the thymus (Uehara et al., 2002). CCR9+ pDCs
efficiently induce Treg cells from peripheral T cells, inhibiting
Ag-specific immune responses and graft-versus-host disease
(GVHD). The involvement of CCR9 in T cell progenitor recruit-
ment to the thymus and the known expression of its chemokine
ligand CCL25 by thymic epithelial cells led us to ask whether
CCR9 might target peripheral pDCs to the thymus. We present
studies here that illustrate the importance of CCR9 in targeting
pDCs to the thymus and demonstrate a CCR9-dependent role
for pDCs in central tolerance to extrathymically acquired Ag.
RESULTS
CCR9 Regulates pDC Homeostasis in the Thymus
We initially askedwhether CCR9 deficiency alters pDC represen-
tation in the thymus and, for comparison, in peripheral lymphoidtissues and blood. Ccr9/ mice had substantially fewer thymic
pDCs than did wild-type (WT) mice (Figure 1A), whereas CCR9
deficiency had no major impact on pDC numbers in peripheral
lymphoid tissues. In contrast, Ccr9/ mice present with higher
pDC numbers in the blood compared to WT mice, probably re-
flecting reduced gut homing. CCR9 deficiency had no significant
effect on the representation of cDCs in the blood or peripheral
lymphoid tissues or that of migratory (SIRPa+) or resident
(SIRPa) cDCs in the thymus (Figure S1A available online). We
used a relatively stringent CD11chi gate to define cDCs (linea-
geB220PDCA-1, CD11chi cells), because CD11c interme-
diate gating includedmany events with low and abnormal scatter
properties (Figure S1A); in comparison to previous studies (Li
et al., 2009), our analyses therefore show fewer cDCs than
pDCs in the WT thymus.
To compare the ability of Ccr9/ versus WT hematopoeitic
cells to replenish thymic pDCs in a common host environment,
we reconstituted irradiated F1 (CD45.1+CD45.2+) recipients
with equal numbers of congenic WT CD45.1+ and Ccr9/
CD45.2+ bone marrow (BM) cells. To control for potential
CCR9-independent differences between CD45.1 and CD45.2
donor cells, ‘‘control chimeras’’ were also created in which
both CD45.1 and CD45.2 BM donors were WT. At 8–12 weeksImmunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc. 439
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and DC pools are fully reconstituted, we determined the ratio
of CD45.1+ to CD45.2+ donor-derived cells among pDCs
(lineageCD11cintB220+ cells) in the thymus and other tissues
(Figure 1B) and among thymic migratory and resident cDCs (Fig-
ure S1B). To normalize for variations in stem cell numbers from
donor mice and stochastic differences in stem cell engraftment
between recipients (Baekkevold et al., 2005), these ratios were
divided by the ratio of CD45.1+ to CD45.2+ donor-derived splenic
B cells, which do not require CCR9 for their development and
long-term splenic recruitment. The mean CD45.1/CD45.2 ratio
among splenic B cells was not significantly different between
control and experimental bone marrow chimeric (BMC) mice,
consistent with the hypothesis that CCR9 deficiency does not
affect stem cell engraftment (data not shown). In some experi-
ments, recipient mice received a Fms-like tyrosine kinase ligand
(Flt3L)-secreting subcutaneous (s.c.) tumor 10–14 days prior to
analysis to expand DC numbers in vivo (Figure 1C).
Compared to control chimeras, where WT CD45.1+ and
CD45.2+ DCs were equally represented in all tissues, mixed
WT-Ccr9/ chimeras exhibited predominantly WT pDCs in the
reconstituted intraepithelial compartment (IEL), and to a lesser
extent in the lamina propria (LP) of the small intestine, consistent
with the role of CCL25 in small intestinal pDC homing (Wendland
et al., 2007). Moreover, WT-derived BM cells were more efficient
than Ccr9/-derived BM cells at repopulating the thymic pDC
pool. In contrast, WT pDCs had no advantage in populating
the peripheral lymphoid tissues studied. Among thymic cDCs,
a 2-fold increase in the representation of WT over KO resident
SIRPa cDCs was observed, but with no major effect on the
migratory SIRPa+ cDC compartment (Figure S1B): this may
reflect the known contribution of CCR9 to thymic recruitment of
BM precursors. Results in untreated BMCs were similar to those
in which DCs were expanded in vivo after s.c. injection of the
Flt3L-secreting tumor inBMCs (Figures 1Band1C).Weconclude
that CCR9 controls pDC representation in the thymus by
affecting either their development or localization to the thymus.
CCR9 Mediates Peripheral pDC Recruitment to the
Thymus
To determine whether CCR9 is required for endogenous pDC
recruitment to the thymus, we surgically joined WT (CD45.1)
and Ccr9/ (CD45.2) mice at the flanks to establish a shared
circulation. Three weeks after parabiotic union, very few
(<0.5%) thymocytes were partner derived, ruling out exchange
of hematopoietic precursors (data not shown). More importantly,
WT pDCs accessed the Ccr9/ partner thymus well: in fact, the
percentage of WT pDCs in the Ccr9/ thymus exceeds that
in the Ccr9/ partner’s blood, indicating that WT pDCs have a
substantial advantage over host Ccr9/ pDCs in accessing or
surviving in the Ccr9/ thymus (Figures 2A and S2). In contrast,
Ccr9/ pDCs enter the WT partner thymus poorly: the ratio of
Ccr9/ to WT pDCs is much lower in the WT partner thymus
than that of WT to Ccr9/ pDCs seen in the Ccr9/ partner
thymus. This difference is not attributable to differences in blood
exchange, as shown by the fact that in the WT parabiont, the
frequency of partner-derived Ccr9/ pDCs in blood was larger
than that seen in the thymus (Figures 2A and S2). However, the
number of pDCs recovered from unmanipulated Ccr9/ mice440 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.is substantially reduced from that in WT mice. Therefore, we
also determined total pDC numbers per million live thymocytes
(Figure 2B) or per total thymus (data not shown) and found that
the number ofWT pDCs recovered fromCcr9/ parabiont thymi
is also significantly elevated (p < 0.005) compared to the
numbers of Ccr9/ thymic pDCs recovered from WT parabiont
thymi, 3 weeks after parabiotic union (Figure 2B). Interestingly,
the blood levels of donor Ccr9/ pDCs in WT parabionts is
elevated relative to WT pDCs in Ccr9/ parabionts, presumably
reflecting a decreased ability of the Ccr9/ pDCs to enter
tissues (especially the intestines) of the WT host, whereas the
exchange of pDCs in peripheral lymphoid tissues is not affected
by CCR9 deficiency (Figures 2A and S2).
To further confirm a role for CCR9 in pDC recruitment from the
blood, we next assessed the ability of Ccr9/ versus WT pDCs
to home into the thymus after i.v. injection. Thymic progenitor
cells use a classical multistep adhesion cascade to home to
the thymus, involving P-selectin-mediated rolling, CCR9- and
CCR7-dependent activation, and a4b1-mediated arrest on
VCAM-1+ venules in the thymic corticomedullary junction
(Krueger et al., 2010; Scimone et al., 2006; Zlotoff et al., 2010).
Bulk DC populations from the spleen use the same adhesion
molecules to enter the thymus, although the chemoattractant
receptor(s) involved are unknown (Bonasio et al., 2006). Flow cy-
tometric studies reveal that CCR9+ pDCs from peripheral
lymphoid tissues which express classical lineage markers such
as PDCA-1 and Siglec-H and low to intermediate expression
levels of costimulatory markers (CD40, CD80, CD86, and MHC
class II) also display both a4 and b1 integrin chains and bind
chimeric P-selectin Ig (Figure 3A). In comparison, cDCs ex-
pressed even higher levels of a4, b1, and P-selectin ligands but
they stain poorly for CCR9. pDCs and cDCs from Flt3L-treated
donors displayed the same expression of trafficking receptors
and overall surface phenotype as did their counterparts from
normal donor mice (Figure 3B). 48 hr competitive homing studies
were carried out with purified pDC populations from donors
exposed to Flt3L to expand DC numbers in vivo, because suffi-
cient DC numbers for homing studies could not be obtained
from untreated donor mice. Flt3L has been shown to be a potent
growth factor for DCs that does not affect their activation (Gilliet
et al., 2002). Purified CCR9-deficient CD45.2+ pDCs or WT
control CD45.2+ pDCs were mixed with equal numbers of puri-
fied congenic WT CD45.1+ pDCs and injected i.v. into normal
F1 (CD45.1+CD45.2+) WT recipients. Flow cytometric analysis
of homed pDCs on day 2 showed that a larger ratio of WT
(CD45.1+) to Ccr9/ (CD45.2+) donor pDCs localized to the
thymus (Figures 4A and S4), whereas their localization in periph-
eral lymphoid tissues and bloodwas similar. In controlmice, both
CD45.1+ and CD45.2+ donor WT pDCs had comparable thymic
homing efficiencies. The results are consistent with a specific
role for CCR9 in peripheral pDC recruitment to the thymus.
Toll-like Receptor Stimulation Inhibits pDC Homing
to the Thymus
Toll-like receptor (TLR) agonists, which mimic infectious stimuli,
activate pDCs, altering their phenotype and function from a tol-
erogenic to an immunostimulatory state (Colonna et al., 2004).
To evaluate whether infectious stimuli alter trafficking receptor
expression and homing properties of pDCs, we stimulated the
Figure 2. Migration of Endogenous pDCs to the Thymus Is CCR9 Dependent
Congenic WT (CD45.1) and Ccr9/ (CD45.2) mice were surgically joined at the flanks to establish anastomosis. Thymi, peripheral lymph nodes (PLN), and blood
were harvested after 3 weeks and analyzed for expression of allelic CD45.1 and CD45.2 markers by flow cytometry among partner-derived, fully differentiated
pDCs (LinCD11cintPDCA-1+).
(A) Bar graphs show mean percentage of partner-derived pDCs in parabiotic mice with error bars representing the SEM (n = 7 mice).
(B) Bar graphs represent mean number of pDCs per million live cells ± SEM (shown as error bars), with seven mice per group.
Data pooled from two experiments. See also Figure S2.
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expressed higher levels of MHC class II and costimulatory
CD86 (B7-2)molecules; they also displayed enhanced P-selectin
binding and slightly upregulated a4 and b1 integrin expression
levels, but they downregulated CCR9 (Figure S3). In short-term
homing assays, resting pDCs localized much more efficiently
from the blood to the thymus than did CpGA-treated pDCs:
The ratio of activated to resting pDCs is much lower in the
thymus than in the blood at 36–48 hr postinjection (Figure 4B).
This is not due to a loss in pDC viability after TLR stimulation,
because overnight stimulation with CpGA had no major effect
on the number of viable cells recovered (data not shown), and
the levels of unactivated (CD45.2+) versus activated (CD45.1+)
donor pDCs were comparable in the blood 36–48 hr after i.v.
injection (Figure 4B). Activation also inhibited localization of
pDCs from the blood to the peripheral lymph tissues and to
a lesser extent to the spleen. In sum, resting pDCs home to the
thymus in a CCR9-dependent fashion and thymic homing
capacity is compromised upon activation with a potent TLR
stimulus.
Ag-Loaded pDCs Induce Central Tolerance
Given that the thymus recruits unactivated pDCs in a CCR9-
dependent fashion, we hypothesized that CCR9+ pDCs couldefficiently transport peripheral Ags acquired in a tolerogenic
context to the thymus and induce negative selection by Ag
presentation to developing thymocytes. To evaluate the role of
Ag-loaded pDCs on thymic development of Ag-specific thymo-
cytes, lethally irradiated CD45.1 congenic B6 mice were recon-
stituted with lymphocyte-depleted BM cells from the same
CD45.1 congenic B6 mice and CD45.2+ transgenic OT-II Rag1
(recombination-activating gene 1)-deficient mice. Thymocytes
developing from the OT-II Rag1/ BM exclusively express the
OT-II TCR, specific for chicken ovalbumin (OVA)-derived peptide
(OVAp). This system allows us to compare changes in devel-
oping OVA-specific thymocytes (CD45.2-derived) in the context
of a diverse polyclonal CD45.1-derived thymocyte pool. Two
weeks after BM reconstitution, when intrathymic T cell develop-
ment is well under way, mice were injected i.v. with either
50 nmoles of OVAp as a positive control, or with two to five
million purified pDCs that were either untreated or loaded with
OVAp followed by extensive washing to eliminate free peptide.
OVAp-loaded pDCs were as effective as soluble OVAp at elimi-
nating CD45.2+ OT-II OVA-specific CD4+CD8 single-positive
(SP) (Figures 5A and 5B) but not CD4+CD8+ double-positive
(DP) (Figures S5A and S5B) thymocytes, whereas pDCs not
loaded with Ag had no effect on either thymocyte population.
Furthermore, activation of OVAp-loaded pDCs with CpGAImmunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc. 441
Figure 3. Immature pDCs in Peripheral Lymphoid Tissues Express Trafficking Receptors Involved in Thymic Homing
Staining of peripheral lymph nodes from normal untreated C57BL/6 mice (A) and Flt3L-B16-inoculated mice (B) for DC lineage markers (PDCA-1, SiglecH, CD8a,
CD11b, and MHC class II); costimulatory ligands (CD40, CD80, and CD86); and trafficking receptors (CCR9, a4 and b1 integrins, and P-selectin binding ligands).
DC subsets were analyzed by flow cytometry by gating on pDCs (LinCD11cintB220+, red histogram plots) and cDCs (LinCD11chiB220, blue histogram plots).
Shaded histogramplots represent isotype controls, or in the case of P-selectin binding, incubation in the presence of 5mMEDTA. Data representative of fivemice
per experiment from a total of three experiments. See also Figure S3.
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(Figures 5A and 5B). In separate experiments, we evaluated the
intrathymic localization of adoptively transferred peripheral
pDCs by immunohistochemistry (Figure 5C). Most pDCs localize
in the medulla and corticomedullary junction (Figure 5C). Thus,
Ag-loaded pDCs injected i.v. localize predominantly in thymic
microenvironments associated with negative selection of devel-
oping thymocytes; homed pDCs are effective at deleting Ag-
specific CD4 thymocytes and prior activation of pDCs with
TLR ligands abrogates their homing and ability to effect clonal
deletion.
Thymic Clonal Deletion by Thymotropic pDCs Is CCR9
Dependent
To determine whether CCR9 expression on pDCs is required for
negative selection of Ag-specific OT-II thymocytes, we sorted
pDCs from Flt3L-treated WT and Ccr9/ mice, loaded them
with OVAp, and transferred them into the B6 (CD45.1)-OT-II
Rag1/ (CD45.2) BMC mice as described above. In contrast
to the efficient deletion of OT-II thymocytes by WT pDCs,
Ccr9/ pDCs had no effect on the Ag-specific thymocyte pop-
ulation (Figures 6A and 6B). The failure of OVAp-loaded activated
pDCs (Figure 5) or peptide-loaded Ccr9/ pDCs (Figure 6) to
mediate clonal deletion rules out the possibility that negative
selection is due to OVAp released from loaded DCs. In addition
to deletion of Ag-specific thymocytes, central tolerance can also
be mediated by the conversion of Ag-specific developing T cells
into natural Treg cells that express the transcription factor
Foxp3. However, we did not observe induction of Foxp3 expres-
sion on OVA-specific OT-II T cells (Figure 6C).442 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.It remained a formal possibility that CCR9-deficient pDCs ob-
tained from Ccr9/ donors had compromised tolerogenic
potential, similar to TLR-activated pDCs. In direct cellular inter-
action assays, with in vitro thymic reaggregation studies,
OVAp-loaded WT or Ccr9/ pDCs were equally potent in
deleting OT-II thymocytes 72–98 hr after reaggregation of OT-II
Rag1/ thymocytes and thymic stromal elements with either
Ag-loaded WT or Ccr9/ pDCs (Figure S6). Loss of Ag-specific
CD4+ OT-II thymocytes occurred by apoptosis as evidenced by
elevated Annexin V (AnnV) expression levels, and among the few
remaining OT-II thymocytes there was no Foxp3 expression.
Control DCs that were not loaded with OVAp did not induce
thymic deletion of OT-II thymocytes. Thus, immature pDCs do
not require CCR9 to mediate clonal deletion in direct cellular
interaction assays; rather, they use CCR9 to home to the thymus,
where they induce central tolerance to imported Ags.
Endogenous pDCs Transport Endocytosed Soluble
and Particulate Antigens to the Thymus
To determine whether endogenous pDC populations have the
capacity to transport peripheral Ags to the thymus, we used
fluorescence-labeled dextrans and microspheres (0.2 mm in
diameter), which are efficiently endocytosed by immature DCs
without inducing their maturation, as models of innocuous
soluble or particulate tissue molecules. Two days after s.c. injec-
tion of yellow-green (YG)-labeled beads, fluorescent pDCs were
readily detected in draining LN, but not in the distal MLN (Fig-
ure 7A). More importantly, fluorescent pDCs were detected in
the thymus after fluorescent dextran or bead injection (Figures
7A and S7B) and soluble Ag was incorporated into discrete
Figure 4. Homing of pDCs to the Thymus Is CCR9 Dependent and Is
Prevented by pDC Activation
Pooled peripheral lymph nodes from B16-Flt3L-inoculated WT (CD45.2),
congenic WT (CD45.1), and Ccr9/ (CD45.2) mice were enriched for pDCs by
MACS technology.
(A)Ccr9/ (CD45.2) pDCs (experimental group) or WT (CD45.2) pDCs (control
group) were coinjected i.v. with an equal number ofWT (CD45.1) pDCs intoWT
F1 (CD45.1 3 CD45.2) mice. After 48 hr, tissues were harvested and cell
suspensions were analyzed by flow cytometry for CD45.1 andCD45.2markers
among gated pDCs (LinCD11cintB220+). Bar graphs depict relative localiza-
tion ratios obtained by dividing the CD45.1/CD45.2 pDC ratio in each tissue by
the same ratio in the input (injected) sample. Error bars represent the SEM.
(B) Equal numbers of WT unactivated (CD45.1) and CpGA-activated (CD45.2)
pDCs were coinjected i.v. (input total of 5 3 106 after overnight harvest) into
syngeneic F1 (CD45.1 3 CD45.2) recipients. Tissues were analyzed by flow
cytometry after 36–48 hr. Results are presented as the number of homed
CD45.1+ (unactivated, open bars) or CD45.2+ (activated, black bars) pDCs
recovered per million total tissue or blood pDCs (LinCD11cintB220+ cells),
divided by the number of million pDCs injected.
Histogram represent means ± SEM (standard error of the mean) from four to
five recipient mice in one experiment and are representative of three experi-
ments with similar results. See also Figure S4.
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which like pDCs represent amigratory DC subset, also contained
transported beads (Figure S7A) or dextran (Figure S7F). The
frequency of Ag-positive SIRPa+ cDCs was variable, but
in general somewhat less than that of pDCs in experiments with
fluorescent dextrans (Figure S7F). In contrast, resident (nonmi-
gratory) thymic SIRPa cDCs, which have been shown to accu-
mulate soluble fluorescent protein Ags injected i.v. (Li et al.,
2009), did not acquire comparable levels of labeled dextran (Fig-
ure S7F; or fluorescent beads shown in Figure S7A), even though
all thymic DC populations, including resident SIRPa cDCs,
efficiently endocytosed labeled dextran ex vivo (Figure S7G).
To confirm that particulate or soluble Ag was transported to
the thymus within cells, we inhibited DC recruitment by blocking
with a4 mAb (Figures 7B and S7C; Bonasio et al., 2006). Treat-ment with a4 mAb decreased the number of fluorescent pDCs
found in the thymus 2 days after either YG-labeled bead (Fig-
ure 7B) or FITC-dextran (Figure S7C) injection. Moreover, thymic
localization of Ag-bearing pDCs was dramatically reduced in
Ccr9/ mice (Figures 7B and S7C). Neither a4 mAb treatment
nor CCR9 deficiency altered endocytic uptake by peripheral
DCs, as shown by the fact that the mean fluorescence intensity
(MFI) of FITC signal in pDCs from the draining lymph nodes,
blood, and spleen was similar after s.c. injection of FITC-dextran
(data not shown). Thus, peripherally injected soluble (FITC-
dextran) or particulate (YG-bead) Ags are transported into the
thymus by migratory pDCs.
CpGACoinjection Prevents pDC Transport of Peripheral
Ags to the Thymus
Central tolerance to Ags associated with infectious pathogens is
undesirable. To mimic Ag presentation in conjunction with infec-
tious agents, YG beads or FITC-dextran were coinjected s.c.
with CpGA in situ. CpGA coinjection substantially reduced the
numbers of fluorescent bead- or dextran-containing pDCs local-
izing to the thymus (Figures 7B and S7C), consistent with the
effects of CpGA on thymic pDC homing seen in our short-term
homing studies (Figure 4B). The number of fluorescent-labeled
pDCs in the LN draining the injection site was greatly increased
by the treatment (data not shown). Therefore, activation of tissue
pDCs in situ by infectious signals prevents their localization to
the thymus.
Tissue Antigens Are Taken up Locally in Tissues or
Draining LN for Thymic Transport
It remained possible that the injected Ags disseminated beyond
the local draining LNs and were endocytosed by circulating
pDCs in the blood. To address this possibility, we injected YG-
and crimson-labeled beads separately into the left and right
legs below the knee. Control animals received Ag of only one
color or a mixture of the two colors injected in both legs. We
reasoned that if particles were taken up primarily in the blood
after Ag dissemination, then thymic homing pDCs should have
endocytosed equal numbers of YG and crimson beads even
when the two colors were injected separately into the left and
right footpads. Conversely, if Ags were primarily endocytosed
in the tissues or local draining LNs, then thymic-homed pDCs
would have a predominance of YG or crimson beads, but not
both. Injection of a mixture of YG and crimson bead Ags into
the legs provided a control to show that pDCs could in fact incor-
porate both colors of beads. As illustrated in the FACS plots (Fig-
ure 7C), after injection of YG and crimson beads in separate legs,
the majority of fluorescent thymic pDCs contain a predominance
of beads of one or the other color. In contrast, after injection of
mixed beads, many of the fluorescent thymic pDCs contain
beads of both colors. Among thymic pDCs containing two or
more beads, 30%–60% contained only YG or only crimson
beads after injection of a different color in each leg. In contrast,
in mice that received the bead mixture, more than 90% con-
tained both YG and crimson beads. This experiment clearly
demonstrates that locally acquired tissue Ags can be trans-
ported to the thymus by peripheral pDCs.
Similar results were obtained when FITC and Alexa Fluor 647
(AF647) fluorescent dextrans were injected into the left and rightImmunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc. 443
Figure 5. Deletion of OVA-Specific Thymocytes by
Unactivated, but Not CpG-Activated, OVA-Loaded
pDCs
BMCs were prepared by reconstituting irradiated WT
(CD45.1) recipient mice with equal numbers of BM cells
from WT (CD45.1) and OT-II Rag1/ (CD45.2) donor
mice, whose T cells express an OVA-specific TCR.
14 days after reconstitution, mice were either untreated or
injected i.v. daily for 2 consecutive days with 2–5 3 106
unpulsed (pDC) or OVAp-pulsed pDCs that were either
unactivated (pDC/OVA) or stimulated with CpGA in vitro
(pDC/OVA+CpGA). As a positive control for thymic dele-
tion of OVA-specific T cells, mice were injected i.v. with
50 nmol of soluble OVAp in PBS. Thymocytes were
analyzed 2 days after final pDC orOVA treatment by gating
on LinCD4+CD8 single-positive (SP) cells to assess the
frequency of the CD45.2+ OVA-specific population.
(A) Representative FACS plots illustrating deletion of OT-II
T cells (CD45.2+) by sorted, OVAp-loaded unactivated
pDCs, but not by unpulsed or CpGA-activated pDCs.
(B) Mean percent of OVA-specific CD45.2+ cells among
CD4 SP thymocytes, with error bars representing the SEM
(n = 5). Representative of three experiments with similar
results.
(C) Location of donor-derived pDCs in the thymus by
immunofluorescence. Normal WT (CD45.2) mice were
injected intravenously with purified pDCs from congenic
WT (CD45.1) mice. 48 hr later, thymi were snap frozen
and cryosections were stained with Hoechst, a lectin
delineating the medulla (UEA-1), and with anti-mouse
CD45.1. Colocalization of DAPI and CD45.1 in overlay
(middle) panel shows the homed pDCs (white arrows).
Merged section with UEA-1 is shown in far right. The
cortical (C) and medullary (M) regions are depicted in
the top panel. Higher magnification (403, oil immersion) in lower panel, depicting colocalization of transferred CD45.1+ pDCs (CD45.1 shown in red with cell
nuclei shown with DAPI staining in blue and CD11c staining in green). Representative of seven thymi studied.
See also Figure S5.
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dextran dissemination as expected of a soluble Ag, all labeled
thymic pDCs in this experiment gave both FITC and AF647 fluo-
rescence signals. However, the homed pDCs clearly separated
into two distinct subsets, one predominantly AF647+ and the
other predominantly FITC+ (Figure S7E). Similarly distinct
subsets were seen in blood (not shown) and spleen (Figure S7E).
In the spleen, which contained more labeled pDCs, a distinct
fraction of pDCs were more equally labeled (had an intermediate
AF647/FITC fluorescence ratio); these presumably represent
pDCs that had incorporated only systemically disseminated
dextrans.
We conclude that endogenous pDCs transport both particu-
late and soluble tissue Ags to the thymus and that this transport
is mediated by CCR9 and a4 integrins and is inhibited by TLR
stimulation.
DISCUSSION
Our studies demonstrate that unactivated pDCs from peripheral
lymphoid tissues have the capacity to home to the thymus.
CCR9 expression on immature pDCs imparts this thymic homing
capacity, allowing them to carry innocuous Ags from the
periphery to the thymus, where they can delete developing Ag-
specific thymocytes and contribute to central tolerance. Infec-444 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.tious signals downregulate CCR9 on pDCs and limit their thymic
homing capacity, preventing inappropriate deletion of pathogen-
specific T cells. We have previously shown that CCR9 expres-
sion defines immature pDCs in lymphoid tissues of mice, with
potent immunosuppressive properties both in vitro and in vivo
(Hadeiba et al., 2008). The demonstration here that CCR9-ex-
pressing pDCs mediate central as well as peripheral tolerance
underscores their central role in maintaining immune homeo-
stasis and tolerance.
CCR9 was required for efficient pDC participation in central
tolerance in our studies. Compared toWT pDCs, CCR9-deficient
pDCs homed poorly to the thymus after i.v. transfer and accumu-
lated in reduced numbers in the thymus of mixed BM chimeras.
In CCR9-deficient mice, endogenous thymic pDCs were
reduced in frequency, and in parabiosis studies, CCR9-deficient
pDCs failed to enter the WT thymus well; in fact the number of
Ccr9/ pDCs recovered from the WT thymus (which repre-
sented <5% of thymic pDCs) was still lower than the number
of WT pDCs recovered from the Ccr9/ thymus even after pro-
longed vascular anastomosis, despite higher levels of CCR9-
deficient pDCs in the blood of WT parabionts. CCR9 deficiency
did not affect the level of pDC exchange in peripheral LNs which,
as in other studies, was incomplete: Liu et al. (2007) reported
a plateau of 12%–18% exchange in LNs even in long-term para-
bionts and proposed that LN pDCs are continually replaced by
Figure 6. Thymic Clonal Deletion of OVA-Specific Transgenic T Cells by OVA-Loaded WT but Not by Ccr9–/– pDCs
BMCs were prepared as in Figure 5, and 14 days later, mice were either untreated or injected i.v. for 2 consecutive days with 2–53 106 sorted WT (WT pDC) or
Ccr9/ (KO pDC) OVAp-loaded pDCs. Mice treated i.v. with soluble OVAp served as a positive control. Thymocytes were analyzed 2 days after final pDC or
OVAp treatment, by gating on LinCD4+ SP cells to assess the frequency of the OVA-specific CD45.2+ population.
(A) Representative FACS plots illustrating deletion of OVA-specific (CD45.2+) OT-II T cells by WT but not Ccr9/ OVA-loaded pDCs.
(B) Mean percent of OVA-specific CD45.2+ cells among CD4+ SP thymocytes, with error bars showing the SEM (n = 5).
(C) Representative FACS plots illustrating lack of Foxp3+ Treg cell induction among OVA-specific (CD45.2+) thymocytes. Quadrant gates were set based on
isotype controls.
Representative experiment from a total of three. See also Figure S6.
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tion and do not recirculate, and because of this are poorly
exchanged through the limited capillary network joining the para-
bionts. Ag-loaded CCR9-deficient pDCs failed to mediate clonal
deletion of Ag-specific thymocytes in vivo, and this deficiency re-
flected the role of CCR9 in homing as indicated by the fact that
CCR9-deficient pDCs were fully capable of mediating clonal
deletion of thymocytes in ex-vivo-reconstituted thymic organ
cultures. In contrast to our findings, previous studies reported
that blockade of the CCR9 ligand CCL25 did not prevent bulk
splenic DCs from inducing central tolerance (Bonasio et al.,
2006). However, pDCs represent only a minor subset of splenic
DCs (Alvarez et al., 2008; Villadangos and Heath, 2005) and, as
discussed below, subsets of peripheral cDCs probably partici-
pate in central tolerance as well. Interestingly, CCR9 deficiency
did not completely abrogate pDC recruitment to the thymus in
our experiments, suggesting the potential for additional, overlap-
ping homing mechanisms. Recent studies have established
a role for CCR7, in addition to CCR9, in recruitment of T cell
precursors to the thymus (Krueger et al., 2010; Zlotoff et al.,
2010). However, it seems unlikely that thymus-expressed
CCR7 ligands are involved in thymic pDC recruitment: CCR9+
pDCs displayed poor chemotactic responses to CCR7 ligands
(e.g., CCL21) (Hadeiba et al., 2008), and CCR7 is usually upregu-
lated on activated DC populations, which migrated poorly to the
thymus in this and other studies (Proietto et al., 2009).In agreement with previous studies implicating P-selectin and
a4 integrins in thymic DC homing (Bonasio et al., 2006; Scimone
et al., 2006), we found that pDCs expressed a4 and functional
binding sites for P-selectin and that endogenous thymic pDC
migration was inhibited by a4 integrin blockade. Thus, peripheral
pDC homing to the thymus probably employs the same thymic
recruitment cascade used by T cell progenitors and bulk splenic
DCs.
The role of pDCs in peripheral tolerance is well established and
usually involves immature or unactivated pDCs mediating the
induction of adaptive Treg cells in peripheral lymphoid tissues
(Hadeiba et al., 2008; Morelli and Thomson, 2007). The results
presented here, however, suggest that migratory pDCs can
also continuously transport peripheral Ags to the thymus and
contribute to central tolerance. This mechanism may be an
important complement to AIRE-dependent transcription of TSA
by mTECs, which are known to express many but not all periph-
eral self-Ags for central tolerance (Aschenbrenner et al., 2007).
In contrast, thymic DCs, including pDCs, lack expression of
the transcription factor AIRE and have high endocytic activity
(Hubert et al., 2008). Therefore, a primary role of thymic pDCs
may be to present peripherally endocytosed TSA such as
secreted proteins or Ags shed from apoptotic cells that are not
present in the circulation at tolerogenic levels and are not
adequately expressed or presented by mTECs (Proietto et al.,
2009). Alternatively, it is interesting to consider that pDCs mayImmunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc. 445
Figure 7. Endogenous pDCs Take up Peripheral Particulate Ags and Migrate to the Thymus
WT or Ccr9/mice were injected s.c. at the base of the tail with yellow-green (YG) fluorescent microspheres. Cohorts of WT mice were also treated with either
CpGA in situ, by mixing YG fluorescent microbeads with CpGA and injecting s.c. or with a4 mAb injected i.v. every 12 hr. 48 hr after bead injection, lymphoid
tissues and blood were harvested and analyzed by flow cytometry.
(A) Representative histograms showing YG bead (FITC channel) signal in gated LinCD11cintB220+PDCA-1+ pDCs in thymi, draining lymph nodes (draining LN),
mesenteric lymph nodes (MLN), spleen, and blood of WTmice given YG beads s.c.; gray-shaded plots are pDCs frommice that received unlabeled microbeads.
Results are representative of three experiments.
(B) Mean number of YG bead+ pDCs (LinCD11cintB220+) per million live cells in thymi from WT mice injected either with unlabelled microbeads, YG beads, YG
beads with CpGA, or a4 mAb or in thymi fromCcr9
/mice injected with YG beads. Error bars represent SEMof results from fivemice from one experiment of two
performed with similar results.
(C) WT mice received s.c. injections of (1) YG beads (YG) alone in the left leg; of (2) crimson beads (Crms) alone in the right leg; of (3) YG beads in the left leg and
Crms beads in the right leg; or of (4) a mixture of YG and Crms beads in both legs. Representative FACS plots of gated thymic pDCs (LinCD11cintPDCA-1+) with
the percent of pDCs containing only YG beads, only Crms beads, or both bead colors. The red gates enclose pDCs that contain two or more beads. Pooled data
from four to five mice per cohort are summarized in the histograms: the top panel presents the number of thymic pDCs that contain one or more colored beads
(YG only as green bars, Crms only as red bars, or both as yellow bars) in mice receiving either mixed YG+ Crms beads in both legs or separate beads in each leg.
The bottom histogram focuses on thymic pDCs that contain two or more colored beads: it shows the percent of these pDCs that contain only YG beads
(green bars), only Crms beads (red bars), or both (yellow bars) from mice receiving either mixed YG+Crms beads in both legs or separate beads in each leg.
Results are representative of two experiments. Error bars represent the SEM.
See also Figure S7.
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Ags from food or innocuous flora in the digestive tract. Indeed, as
shown here and in a previous study (Wendland et al., 2007),
CCR9 mediates pDC localization to the intraepithelial compart-
ment of the gut wall, a site well positioned to sample Ags in the
gut lumen. Evidence for thymic tolerance to innocuous fed Ags
comes from a recent study in which oral tolerance to myelin
basic protein (MBP) failed if mice were thymectomized prior to
MBP feeding (Song et al., 2006). Whether this involves central
tolerance mechanisms and if so whether thymic presentation
of fed Ag is mediated by soluble Ag, or instead by gut DCs that
transport locally endocytosed mucosal Ags to the thymus,
remains to be determined.
In addition to pDCs, a subpopulation of cDCs that express
SIRPa+ and CD11b also enters the thymus from the blood (Don-446 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.skoy and Goldschneider, 2003). It is likely that in addition to
pDCs, thymus-homing cDCs can transport peripheral Ags and
contribute to the control of T cell development. However,
CCR9+ pDCs comprise a major fraction of the rapidly
exchanging migratory DCs in the thymus and, in our experi-
ments, more thymic pDCs than SIRPa+ cDCs contained trans-
ported peripheral Ag (FITC-dextran), suggesting that immature
pDCs may play a more dominant role. Interestingly, migratory
SIRPa+ cDCs in peripheral lymphoid tissues or in the blood circu-
lation stain poorly for CCR9 (data not shown), indicating that they
must use distinct, potentially less efficient, trafficking mecha-
nisms to access the thymus. In fact we find that CCR9 deficiency
does not affect the representation of thymic migratory cDC
subsets; even in BMC mice, we observed no significant effect
of CCR9 on thymic SIRPa+ cDC development or localization.
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through induction of natural Treg cells, as well as by clonal dele-
tion of self-reactive thymocytes. However, OVA-loaded CCR9+
pDCs in our model, and bulk splenic DCs in a previous study
(Bonasio et al., 2006), induced central tolerance through clonal
deletion without Treg cell induction, as indicated by lack of
detectable Foxp3 expression even among surviving Ag-specific
thymocytes. Immature pDCs also effected clonal deletion but
not Treg cell induction in our in vitro Ag-specific thymic reaggre-
gation culture system. The failure of Treg cell induction bymigra-
tory pDCs may be a function of the OT-II TCR-OVA model
system employed in these studies, reflecting unique characteris-
tics of signaling through the transgenic TCR. Alternatively, the
high concentrations of OVAp-loaded MHC complexes on thymic
DCs may dictate the outcome. Several studies have indeed
correlated TCR affinity and signal strength with differential
effects on clonal deletion versus Treg cell induction (Atibalentja
et al., 2009; Jordan et al., 2001; Relland et al., 2009; Starr
et al., 2003). However, it is also possible that pDCs are intrinsi-
cally inefficient at inducing Treg cells in the thymic environment
as shown in a polyclonal thymocyte-DC coculture system, in
which migratory SIRPa+ cDCs, but not thymic pDCs or resident
SIRPa cDCs, induced natural Treg cell development (Proietto
et al., 2008). Thus, it is possible that immature migratory pDCs
effect central tolerance exclusively through clonal deletion,
even though they can induce Treg cells in the periphery. Addi-
tional studies will be required to determine further the impor-
tance of pDC versus migratory or resident cDC populations
and of TCR signaling in Treg cell induction versus clonal deletion
modalities of central tolerance. Moreover, our studies and those
of Bonasio et al. (2006) are restricted to CD4 T cell deletion:
future studies must address the role of transported peripheral
Ag in intrathymic CD8 development as well.
Earlier studies have provided supportive evidence that endog-
enous DCs, under steady-state conditions, can contribute signif-
icantly to thymic tolerance to innocuous peripheral Ags (Proietto
et al., 2009; Bonasio et al., 2006). Here we used fluorescent
dextran and particulate beads as model innocuous peripheral
Ags to follow Ag transport by endogenous pDCs. Subcutaneous
injection labeled a large percentage of pDC and cDCpopulations
in the draining lymph nodes. Importantly, 2 days after local tissue
injection of labeled beads or of FITC-dextran, pDCs, and to
a lesser extent migratory SIRPa+ cDCs, containing endocytosed
model Ags were readily identified in the thymus. In contrast, resi-
dent thymic SIRPa cDCs remained largely negative, ruling out
significant accumulation of Ags passively entering the thymus
from the blood. Interestingly, in most mice injected peripherally
with fluorescent beads, a few thymic SIRPa cDCs (<1%) did
contain one or two beads. These may represent contaminating
migrants in the SIRPa cDC gate or resident cDCs that have
incorporated transported beads released by dying migratory
DCs. In the context of the latter possibility, it is also possible
that OVA-loaded pDCsmay release the antigenic peptide, which
could be taken up by cross-presenting thymic cDCs. Tissue-
specific Ags released from mTECs have been shown to be
cross-presented by thymic DCs and to contribute to central
tolerance (Klein et al., 2009). However, because there is little
fluorescence in SIRPa cDCs after injection of either fluorescent
beads or dextran, it seems more likely that thymic-homed pDCsplay the dominant role in clonal deletion by direct presentation of
transported Ag. The recruitment of dextran- or bead-containing
pDCs was reduced in CCR9-deficient mice and was inhibited by
blockade of the homing receptor a4, confirming the requirement
for thymic-homing mechanisms including CCR9 for endogenous
pDC transport of peripherally endocytosed Ags to the thymus.
Transport of peripheral Ags into the thymus needs to be regu-
lated to prevent deletion of T cells specific to pathogen-associ-
ated molecules. This control may be achieved by modulation
of DC homing properties by infectious agents. pDC activation
with TLR ligands that mimic infectious signals potently limited
thymic homing in our study and also prevented negative selec-
tion of Ag-specific thymocytes by Ag-loaded pDCs transfused
i.v. Similarly, activation of bulk splenic DCs with lipopolysaccha-
ride (LPS) inhibited their migration to the thymus (Bonasio et al.,
2006). Moreover, coinjection of the potent TLR9 ligand CpGA
dramatically inhibited endogenous pDC transport of model Ags
from the periphery to the thymus in our experiments, without
significantly effecting DC endocytosis in the draining LN. Our
in vitro studies showed that peripheral pDC activation downre-
gulated CCR9, without reducing expression of other known DC
thymic trafficking receptors (e.g., a4, b1, or P-selectin binding
sites). Thus, TLR-dependent downregulation of CCR9 may be
an important mechanism to prevent pDC-mediated transport
of pathogen-associated Ags into the thymus, restricting acti-
vated DC populations to the periphery where they can partici-
pate in peripheral T cell activation in lymphoid tissues.
The capacity of peripheral pDCs to ‘‘patrol’’ the thymus and to
contribute to central tolerance is surprisingly efficient. Our short-
term homing studies indicate that the number of homed pDCs is
low compared to endogenously derived thymic pDCs: After
injection of peripheral pDCs, under the same conditions we em-
ployed for clonal deletion studies, only 1%–2% of thymic pDCs
are derived from the injected population. Furthermore, in order to
visualize Ag-specific thymocytes, we created a system with an
artificially high number of Ag-specific thymocytes with our BM
chimeric approach. From our studies, roughly 18% of CD4+
CD8 SP thymocytes in our untreated BMC mice are OVA
specific (CD45.2+) with an average thymic cellularity of 107 cells
after irradiation and BM reconstitution. This translates to 1.8
million Ag-specific SP thymocytes being censored by only
a very small number of pDCs that home to the thymus (roughly
3,000 as determined from our short-term homing experiments).
This ratio of 1 OVA-loaded pDC to 600 OVA-specific SP thymo-
cytes deleted up to 90% of the Ag-specific SP thymocyte
population, which suggests highly efficient and dynamic pDC
scanning of developing thymocytes as they trickle through the
medulla during negative selection. It is interesting to note that
thymus-homing OVA-loaded pDCs delete only SP thymocytes,
whereas OVAp was shown by us and others (Atibalentja et al.,
2009) to drive the deletion of both SP CD4+ thymocytes in the
medulla and also DP thymocytes in the cortex, presumably
reflecting OVA presentation by all MHCII+ cells, including cortical
thymic epithelial cells (cTECs), mTECs, and thymic DCs. Migra-
tory pDCs in our studies localized only in the medulla or the cor-
ticomedullary junction, thus potentially limiting their access to
DP thymocytes, but facilitating their interactions with developing
SP thymocytes. As discussed in a similar context (Bonasio et al.,
2006), intravital microscopy of T cell-DC interactions in LNs hasImmunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc. 447
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Plasmacytoid Dendritic Cells in Central Toleranceshown that single DCs can contact as many as 5,000 T cells per
hour (Miller et al., 2004). Assuming similar contact frequencies in
the thymic medulla of thymocytes with pDCs, this would allow
one Ag-loaded pDC that migrates into the thymus to interact
with (and potentially delete up to) 5,000 3 24 or 120,000 Ag-
specific thymocytes daily. Given about 3,000 thymic-homed
pDCs bearing OVA (and even with repeat scanning events),
these calculations suggest that the homed pDCs could scan
well over 108 SP thymocytes per day, more than enough to
explain our results even if only a fraction of contacts resulted in
deletion. Moreover, neither these considerations nor our studies
take into account the fact that many innocuous Ags are not
encountered in a ‘‘bolus’’ as in our studies, but rather may be
continuously present (e.g., normal tissue or cell constituents,
including normal flora Ags) or frequently encountered (e.g., major
food Ags entering the portal system). In these instances, pDCs
transporting peripheral Ags would be continuously seeding the
thymus, allowing prolonged time periods for thymic T cell
censoring. In sum, our results suggest that only a small number
of Ag-loaded pDCs migrating from the periphery into the thymus
may be needed to censor developing thymocytes of rare
cognate Ag specificity.
In conclusion, our results suggest that immature pDCs con-
tribute to immune tolerance to peripheral Ags through CCR9-
dependent transport of self- or innocuous Ags to the thymus
and subsequent deletion of Ag-specific thymocytes.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (CD45.2) and congenic CD45.1 (B6.SJL-Ptprca Pep3b/BoyJ) mice
were from obtained the Jackson Laboratory (Bar Harbor, ME). TCR transgenic
OT-II Rag1/ mice (C57BL/6-TgN(OT-II.2a)-RAG1tm1Mom) were obtained
from Taconic Farms Inc. (Hudson, NY) through the NIAID exchange program
(Barnden et al., 1998; Mombaerts et al., 1992). Ccr9/ were generously
provided by P. Love (NIH, Bethesda, MD). C57BL/6 F1 (CD45.1 3 CD45.2)
mice were bred in the VMU facility of the Veterans Affairs Palo Alto Health
Care Systems (VAPAHCS). All animal studies were approved by the institu-
tional animal use and care committee and experimentation was conducted
in accordance with AAALAC guidelines.
Reagents and Flow Cytometry
For immunfluorescence and FACS staining, Fc receptors were blocked with
Fc receptor antibody prior to staining with directly labeled or biotinylated
monoclonal antibodies to the Ags indicated in the figures and text. Dead cells
were excluded by propidium iodide or ethidium monoazide staining. The
following mAbs were used for staining: CD3-PECy7 (145-2C11), CD4-Pacific
Blue (RM4-5), CD4-Alexa Fluor 700 (AF700; RM4-5), CD8a-PerCP-Cy5.5
(53-6.7), CD8a-APC (53-6.7), CD11b-PerCP-Cy5.5 (M1/70), CD11b-AF700
(M1/70), CD11c-Pacific Blue (HL3), CD19-PECy7 (1D3), CD25-APC (PC61),
CD40-FITC (3/23), CD45.1-PerCP-Cy5.5 (A20), CD45.2-PerCP-Cy5.5 (104),
B220-PerCP (RA3-6B2), CD80-biotin (16-10A1), CD86-biotin (GL1), NK1.1-
PECy7 (PK136), and CD172a (SIRPa)-PE (P84) from BD Biosciences; and
CD8a-AF700 (53-6.7), CD29 (b1-integrin)-PE (HMb1-1), CD45.1-APC (A20),
CD45.2-FITC (104), CD45.2-PE (104), CD49d (a4 integrin)-PE (R1-2),
SiglecH-FITC (eBio440c), IA/IE-AF700 (M5/114.15.2), and Foxp3-PE
(FJK-16 s) from eBioscience (San Diego, CA). CCR9-APC (242503) was
purchased from R&D Systems (Minneapolis, MN); mAbs to PDCA-1 conju-
gated to either PE or APC were obtain from Miltenyi Biotec (Bergisch
Gladbach, Germany); and B220-Qdot655was obtained from Invitrogen (Carls-
bad, CA). A recombinant mouse P-selectin-human IgG1 Fc fusion protein
(R&D Systems) was used to detect P-selectin ligands. Secondary reagents
included Streptavidin-Alexa Fluor 700 (eBioscience) for the visualization of bio-
tinylated mAbs and anti-human IgG1 Fc-FITC (Jackson Immunoresearch,448 Immunity 36, 438–450, March 23, 2012 ª2012 Elsevier Inc.West Grove, PA) for detection of P-selectin-Ig. Treg cells were fixed, permea-
bilized, and stained with anti-Foxp3-PE (FJK-16 s) according to the manufac-
turer’s recommendation (eBioscience). Neutralizing anti-mouse a4mAb (PS/2)
was purified from hybridoma supernatants.
DC Isolation and Sorting
DCs were isolated from lymphoid tissues of normal mice with Collagenase IV
(Worthington Biochemical Corp., Lakewood, NJ) and DNaseI (Sigma-Aldrich,
St. Louis, MO) in protein-free media at a final concentration of 2 mg/ml and
1 U/ml for 1–2 hr at 37C. For the isolation of Flt3L-expanded DCs, WT or
Ccr9/C57BL/6micewere injecteds.c.with 53106Flt3L-secretingB16mela-
noma cells (Flt3L-B16). After 14 days, designated lymph nodes were harvested
and highly enriched pDC populations (typically >98%) were obtained either by
depletingnon-DCswithpanDCmicrobeads (MiltenyiBiotec) followedbysorting
Lin (CD3CD19NK1.1) CD11cintB220+PDCA-1+ cells or by density gradient
centrifugation over ficoll (Histopaque 1083, Sigma-Aldrich) followed by two
rounds of magnetic bead cell sorting with a pDC isolation kit (Miltenyi Biotec).
pDC Stimulation with TLR Ligands
MACS-purified pDCs from pooled peripheral lymph nodes of Flt3L-B16-in-
jected C57BL/6 mice were cultured at 1–2.5 3 106 cells/ml in complete
RPMI 1640 medium supplemented with 10% FCS for 8–12 hr in the absence
or presence of ODN1585 CpG (1 mM) (Invivogen, San Diego, CA). After stimu-
lation, pDCs were stained for their expression of MHC class II (IA/IE), CD40,
CD80, CD86, CCR9, a4, b1, L-selectin, and for P-selectin binding activity
and in some experiments used in short-term homing studies or in clonal dele-
tion assays (see below).
In Vivo Clonal Deletion Assay
Bone marrow (BM) cells from OT-II Rag1/ (CD45.2+) and WT congenic
C57BL/6 (CD45.1+) mice, depleted of T and B lymphocytes with anti-CD19-
and CD90.2-conjugated microbeads and MACS technology, were injected
i.v. (2–5 3 106 from each BM donor) into lethally irradiated B6.SJL (CD45.1)
recipients. On days 14 and 15 after irradiation, when thymocyte development
from donor BM precursors was underway, mice were treated either with
50 nmol of soluble OVAp (323–339); with 2–5 3 106 WT or Ccr9/ pDCs
pulsed for 1 hr at 37Cwith 50 mMOVA peptide; with 2–53 106 WT pDCs acti-
vated in culture with 1 mM CpGA for 8–12 hr at 37C followed by pulsing with
50 mM OVA peptide for the last 2 hr; or with 2–5 3 106 control unpulsed WT
pDCs. The mice were sacrificed on day 17 after irradiation for analysis of
OVA-specific (OT-II) CD45.2+ thymocytes. In some experiments, thymic Treg
cells (CD4+CD8Foxp3+CD25hi) were enumerated.
Generation of Bone Marrow Chimeras
BM cells from congenic (B6.SJL; CD45.1) WT mice were mixed with equal
numbers of BM cells from either Ccr9/ (CD45.2) or WT (CD45.2) mice
and injected i.v. (2 3 106 BM cells per donor) into lethally irradiated F1
(CD45.1 3 CD45.2) C57BL/6 recipients to generate ‘‘experimental’’ or
‘‘control’’ BMCs, respectively. In separate experiments, reconstituted mice
were injected 2 weeks prior to harvesting tissues, with Flt3L-secreting B16
melanoma cells (as previously described). Tissues and blood were harvested
8–12 weeks after BM transplantation and cell suspensions were stained with
mAbs for flow cytometric analysis.
pDC Homing Assay
pDCs were purified from pooled peripheral lymph nodes of WT (CD45.2), con-
genicWT (CD45.1), andCcr9/ (CD45.2)mice. In experimentalmice, CD45.2+
Ccr9/ pDCs, and in control mice CD45.2+ WT pDCs, were coinjected (2–53
106DCs) i.v. with the samenumber of CD45.1+WTpDCs into syngeneic normal
CD45.1+CD45.2+ F1 WT hosts. After 48 hr, tissues and blood were harvested
and cell suspensions analyzed by flow cytometry. In separate experiments,
CD45.2+ WT pDCs were also stimulated with CpGA as described above and
5–10 3 106 of these activated DCs were coinjected at a 1:1 ratio with unacti-
vated CD45.1+ pDCs into syngeneic CD45.1+CD45.2+ F1 mice.
Parabiosis
8- to 10-week-old female WT (CD45.1) and Ccr9/ (CD45.2) C57BL/6 mice
were anesthetized and joined together by surgical union of skin from the
Immunity
Plasmacytoid Dendritic Cells in Central Toleranceshoulder to knee joints as described (Wright et al., 2001). Mice were kept on
antibiotic water and tissues were harvested 3 weeks later.
In Vivo Fluorescent Microbead Administration
Yellow-green (YG) fluorescent (505/515) carboxylate-modified microspheres
(FluoSpheres) or control unlabeled microspheres (both 0.2 mm diameter;
Invitrogen), were administered in 200 ml (2% suspension) s.c. at the base of
the tail into normal C57BL/6 WT or Ccr9/ mice. In separate cohorts of WT
mice, 200 ml of YG microspheres were coinjected s.c. with 50 nmols of
CpGA (ODN 1585, Invivogen) or mice injected once with YG microspheres
s.c. were also treated with 250–500 mg of a4 mAb i.v. or saline every 12 hr
for 48 hr prior to harvesting the tissues. In separate experiments, mice were
injected with up to 150 ml of YG microspheres in the left leg (footpads and
legs distal to the knee), and crimson fluorescent (625/645) carboxylate modi-
fied 0.2 mm microspheres (FluoSpheres; Invitrogen) in the right leg. Controls
included injections of YG microspheres into the left leg only, injection of
crimson microspheres into the right leg only, and injection of an equal mixture
of YG and crimson microspheres into both the left and right legs. Thymi and
peripheral lymphoid tissues were recovered 48 hr later, and microsphere-con-
taining DCs in cell suspensions were quantified by flow cytometry.
Immunofluorescence Localization of Homed pDC
Purified pDCs from pooled peripheral lymph nodes of Flt3L-B16-injected con-
genic B6.SJL (CD45.1) mice were adoptively transferred (2–5 3 106) into
normal C57BL/6 (CD45.2) mice, and thymi were recovered 48 hr later. Frozen
and fixed 10 mm thymic sections were stainedwith Hoechst (Invitrogen) to label
nuclei, Fluorescein-labeled Ulex Europaeus Agglutinin I UEA-1 (Vector Labs,
Burlingame, CA) as a marker of the thymic medulla, anti-mouse CD11c-Alexa
Fluor 647 (N418, eBioscience) as a pan DC marker, and anti-mouse CD45.1
biotin (A20, eBioscience) followed by streptavidin-Alexa Fluor 594 (Invitrogen)
to identify homed (donor) pDCs.
Statistical Analysis
Data are presented as mean values ± standard error of the mean (SEM) unless
otherwise indicated. Statistical significance between sets of data was as-
sessed with the two-tailed unpaired Student’s t test.
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